436 related articles for article (PubMed ID: 9609139)
1. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
J Cutan Pathol; 1998 Apr; 25(4):204-9. PubMed ID: 9609139
[TBL] [Abstract][Full Text] [Related]
2. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
[TBL] [Abstract][Full Text] [Related]
3. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Schaefer C; Noppen C; Böni R; Kamarashev J; Nestle FO; Spagnoli GC; Dummer R
Am J Pathol; 1997 Dec; 151(6):1549-53. PubMed ID: 9403705
[TBL] [Abstract][Full Text] [Related]
4. T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues.
Jungbluth AA; Iversen K; Coplan K; Kolb D; Stockert E; Chen YT; Old LJ; Busam K
Pathol Res Pract; 2000; 196(4):235-42. PubMed ID: 10782467
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma.
Fetsch PA; Riker AI; Marincola FM; Abati A
Cancer; 2000 Aug; 90(4):252-7. PubMed ID: 10966567
[TBL] [Abstract][Full Text] [Related]
6. Detection of tyrosinase mRNA in formalin-fixed, paraffin-embedded archival sections of melanoma, using the reverse transcriptase in situ polymerase chain reaction.
Guo J; Cheng L; Wen DR; Huang RR; Cochran AJ
Diagn Mol Pathol; 1998 Feb; 7(1):10-5. PubMed ID: 9646029
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody MAT-1 against human tyrosinase can detect melanogenic cells on formalin-fixed paraffin-embedded sections.
Sato N; Suzuki S; Takimoto H; Masui S; Shibata K; Nakano H; Tomita Y
Pigment Cell Res; 1996 Apr; 9(2):72-6. PubMed ID: 8857669
[TBL] [Abstract][Full Text] [Related]
9. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi.
Itakura E; Huang RR; Wen DR; Paul E; Wünsch PH; Cochran AJ
Mod Pathol; 2008 Mar; 21(3):326-33. PubMed ID: 18204435
[TBL] [Abstract][Full Text] [Related]
10. Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes.
Starz H; Haas CJ; Schulz GM; Balda BR
Mod Pathol; 2003 Sep; 16(9):920-9. PubMed ID: 13679456
[TBL] [Abstract][Full Text] [Related]
11. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases 2 and 9 in lentigo maligna melanoma.
Bongiorno MR; Doukaki S; Ferro G; Aricò M
G Ital Dermatol Venereol; 2009 Jun; 144(3):327-9. PubMed ID: 19528914
[No Abstract] [Full Text] [Related]
13. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of redox-state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment.
Hintsala HR; Soini Y; Haapasaari KM; Karihtala P
Histopathology; 2015 Sep; 67(3):348-57. PubMed ID: 25627040
[TBL] [Abstract][Full Text] [Related]
15. Detection of tyrosinase mRNA from the blood of melanoma patients.
Stevens GL; Scheer WD; Levine EA
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
[TBL] [Abstract][Full Text] [Related]
17. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
18. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.
Kunter U; Buer J; Probst M; Duensing S; Dallmann I; Grosse J; Kirchner H; Schluepen EM; Volkenandt M; Ganser A; Atzpodien J
J Natl Cancer Inst; 1996 May; 88(9):590-4. PubMed ID: 8609659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
